The primary patent for liraglutide, the active ingredient in the diabetes medication Victoza, is set to expire in 2023 [1][2]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes [1].
When do other liraglutide patents expire?
Beyond the main patent expiring in 2023, additional patents related to liraglutide formulations and manufacturing processes may extend its market exclusivity. For instance, some secondary patents could extend protection into the late 2020s or early 2030s. These later-expiring patents can sometimes present hurdles for generic manufacturers [3]. Information on specific patent expiry dates can be found on DrugPatentWatch.com [3].
What happens when liraglutide patents expire?
Patent expiration typically opens the door for generic versions of liraglutide to enter the market. Generic drugs are bioequivalent to their brand-name counterparts but are usually offered at a lower price, increasing patient access and competition [4]. The introduction of generics can significantly impact the market share and pricing of the original branded drug [4].
Can biosimilars be made for liraglutide?
Liraglutide is a small molecule drug, not a biologic. Therefore, biosimilar pathways, which are for biologic drugs, do not apply to liraglutide. Instead, generic versions are developed and approved [5].
Who makes liraglutide and its potential generics?
Novo Nordisk is the original manufacturer of liraglutide, marketed as Victoza [1]. Following patent expiry, other pharmaceutical companies can seek approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) to produce and market generic versions of liraglutide [4].
What is the difference between liraglutide and semaglutide?
Both liraglutide and semaglutide are GLP-1 receptor agonists, but they are distinct drugs with different chemical structures and properties. Semaglutide, also developed by Novo Nordisk and marketed as Ozempic (for diabetes) and Wegovy (for weight management), has a longer duration of action, allowing for less frequent dosing compared to liraglutide, which is typically administered daily [6].
What are the risks of using liraglutide?
Common side effects of liraglutide include nausea, diarrhea, constipation, and vomiting. More serious, though less common, risks can include pancreatitis, gallbladder problems, kidney problems, and thyroid tumors [7]. Patients should discuss potential risks and benefits with their healthcare provider [7].
How is liraglutide approved and regulated?
Liraglutide is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) after rigorous clinical trials demonstrate its safety and efficacy for treating type 2 diabetes [1][8]. These agencies oversee drug manufacturing standards and post-market surveillance [8].
---
Sources:
[1] https://www.drugs.com/victoza.html
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are-and-how-they-get-approved
[5] https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biologics
[6] https://www.webmd.com/diabetes/what-is-semaglutide
[7] https://www.niddk.nih.gov/health-information/diabetes/overview/treatment/injectable-medicines
[8] https://www.ema.europa.eu/en/medicines/human/EPAR/victoza